Explore recent issues of Contract Pharma covering key industry trends.
Read the full digital version of our magazine online.
Behind every facility expansion, technology investment, and quality milestone in the CDMO sector is a leadership team making deliberate choices about where to focus, how to grow, and when to take calculated risks.
Stay informed! Subscribe to Contract Pharma for industry news and analysis.
Get the latest updates and breaking news from the pharmaceutical and biopharmaceutical industry.
Discover the newest partnerships and collaborations within the pharma sector.
Keep track of key executive moves and promotions in the pharma and biopharma industry.
Updates on the latest clinical trials and regulatory filings.
Stay informed with the latest financial reports and updates in the pharma industry.
A video roundup of the week’s top industry news stories.
Expert Q&A sessions addressing crucial topics in the pharmaceutical and biopharmaceutical world.
In-depth articles and features covering critical industry developments.
Access exclusive industry insights, interviews, and in-depth analysis.
Insights and analysis from industry experts on current pharma issues.
A one-on-one video interview between our editorial teams and industry leaders.
Listen to expert discussions and interviews in pharma and biopharma.
Contract Pharma Stream offers a centralized destination where users can watch expert-led sessions anytime, anywhere
A detailed look at the leading US players in the global pharmaceutical and BioPharmaceutical industry.
Browse companies involved in pharmaceutical manufacturing and services.
Comprehensive company profiles featuring overviews, key statistics, services, and contact details.
A comprehensive glossary of terms used in the pharmaceutical and biopharmaceutical industry.
Watch in-depth videos featuring industry insights and developments.
Download in-depth eBooks covering various aspects of the pharma industry.
Access detailed whitepapers offering analysis on industry topics.
View and download brochures from companies in the pharmaceutical sector.
Explore content sponsored by industry leaders, providing valuable insights.
Stay updated with the latest press releases from pharma and biopharma companies.
Explore top companies showcasing innovative pharma solutions.
Meet the leaders driving innovation and collaboration.
Engage with sessions and panels on pharma’s key trends.
Hear from experts shaping the pharmaceutical industry.
Join online webinars discussing critical industry topics and trends.
A comprehensive calendar of key industry events around the globe.
Live coverage and updates from major pharma and biopharma shows.
Find advertising opportunities to reach your target audience with Contract Pharma.
Review the editorial standards and guidelines for content published on our site.
Understand how Contract Pharma handles your personal data.
View the terms and conditions for using the Contract Pharma website.
What are you searching for?
400 Professional Drive , Suite 400, Gaithersburg, MD, 20879, US
Avoid Risks and Delays in Bringing your Drug to Market
Released By Emergent Bioservices
Total baseline value for Emergent is approximately $90 million USD, further expanding the collaboration between the companies, which began in February 2021.
For innovators taking on global health risks, rare diseases, or novel medicines, Emergent is an ideal integrated CDMO and a valued partner.
Lenzilumab™ is currently in a Phase 3 clinical trial evaluating patients hospitalized with COVID-19. Humanigen intends to file for EUA first quarter of 2021.
to Develop Emergent’s COVID-19 Hyperimmune Globulin (COVID-HIG) Product Candidate with U.S. Department of Defense Funding
for Johnson & Johnson’s Lead COVID-19 Vaccine Candidate
in Canton Site and Expand Viral Vector and Gene Therapy Capability
for AstraZeneca’s COVID-19 Vaccine Candidate
in Landmark Public-Private CDMO Partnership for COVID-19 Vaccine Development and Manufacturing
for Johnson & Johnson’s Lead Vaccine Candidate for COVID-19
to Expedite Development of Plasma-Derived Therapy for COVID-19
with Vaxart for their Experimental Oral Vaccine Candidate for Coronavirus Disease
for the Treatment and Prevention of Coronavirus Disease
With Novavax for Experimental Vaccine Candidate for Coronavirus Disease
As drug modalities grow more complex, low bioburden powders for reconstitution are emerging as a critical strategy to ensure sterility, stability, and scalability.
Released By Upperton
As part of the investment, Emergent would lead U.S. manufacturing and commercialization efforts for four of Rocketvax’s pipeline candidates.
By: Rachel Klemovitch
Aims to revolutionize pharmaceutical manufacturing with focus on advanced aseptic processing technology.
By: Kristin Brooks
Emergent will add KLOXXADO Nasal Spray to its naloxone product portfolio and will be responsible for all North America product sales and marketing.
By: Charlie Sternberg
The newly acquired facility provides drug product manufacturing services for sterile injectables.
Expands North American footprint with acquisition of Emergent BioSolutions' sterile manufacturing facility in Camden, Maryland.
By: Tim Wright
Comparability of drug substance and drug product manufactured at 2,000L scale achieved.
By: Anthony Vecchione
NARCAN and Smallpox MCM sales drive revenue growth in the quarter.
To reduce investment in CDMO business and operations at facilities in Canton, MA, Baltimore and Rockville, MD, and cut approximately 400 positions.
Emergent will complete activities to advance the development of Ebanga treatment through post-licensure commitments.
Haywood Miller will serve as interim CEO.
The acquisition adds two revenue-generating vaccines for the prevention of cholera and typhoid fever.
The changes are expected to result in annualized savings of over $60 million.
If approved, would be the first 4 mg naloxone nasal spray available OTC in the U.S. for opioid overdose.
Completes acquisition of worldwide rights to TEMBEXA; Anthrax vaccines revenue increases $8.6 million in the quarter.
Enter the destination URL
Or link to existing content
Enter your account email.
A verification code was sent to your email, Enter the 6-digit code sent to your mail.
Didn't get the code? Check your spam folder or resend code
Set a new password for signing in and accessing your data.
Your Password has been Updated !
